Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Long-term clinical study results demonstrated that pramlintide reduces HbA1c and body weight without increasing the frequency of severe hypoglycemia when insulin doses are appropriately co-adjusted, addressing a critical safety concern with insulin intensification strategies
Earlier this week, Centene, a much bigger player in Obamacare, said such enrollment tumbled by 2 million enrollees to 3.58 million at the end of the first quarter compared to 5.54 million at the end of last year and 5.62 million in the year ago quarter
Exercise-dependent absorption: Physical activity increases blood flow to muscles, which can accelerate absorption unpredictably
MKH has grant support from the BBDC New Investigator Award, Canadian Institutes of Health Research, PSI foundation, and holds the Cardy Endowment for Schizophrenia Research Chair
A small retrospective analysis from 2024 suggested modest additional weight loss (13% more) when topiramate was added to semaglutide in patients who had plateaued, but the effect was inconsistent and accompanied by higher adverse-event rates in 40% of participants
:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)
